|
Oct 9
|
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ...
|
|
Oct 7
|
Zacks.com featured highlights include Argenx SE Alphatec and Olin
|
|
Sep 25
|
Amgen stock falls on lackluster drug data
|
|
Sep 25
|
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
|
|
Jul 25
|
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
|
|
Jun 25
|
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
|
|
Jun 25
|
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
|
|
Jun 24
|
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
|
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
|
Jun 24
|
FDA approves argenx’s VYVGART Hytrulo for CIDP treatment
|
|
Jun 21
|
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
|
|
Jan 12
|
How Argenx (ARGX) Stock Stands Out in a Strong Industry
|
|
Jan 2
|
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 22
|
UPDATE 2-European shares end slightly higher ahead of Christmas holiday
|
|
Dec 21
|
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
|
|
Dec 21
|
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study
|
|
Dec 20
|
Stock Market Does Sharp About-Face; Dow Breaks Win Streak
|
|
Dec 20
|
Argenx Crashes 25% As The Setbacks Mount For Its Hallmark Drug, Vyvgart
|
|
Dec 20
|
Argenx autoimmune drug study fails in blow to expansion hopes
|
|
Dec 20
|
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
|